Antihypertensive Drugs Market : Opportunities, Demand and Forecasts, 2019 – 2023

 Global Antihypertensive Drugs Market Research Report: By Therapeutic Class (Calcium Channel Blockers, Beta-adrenergic Blockers, Renin Inhibitors, ACE Inhibitors, Vasodilators, Diuretics, ARBs, Others), By Type (Primary Hypertension, Secondary Hypertension), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites & Online Drug Stores, Others) – Forecast till 2023

Overview

The Antihypertensive Drugs Market is anticipated to grow by US$41,123.2 Million by 2023 rapidly growing at a CAGR of 2.67% during the forecast period. The global antihypertensive drugs market is driven by escalating hypertension cases. These factors have helped shape the antihypertensive drugs market and are expected to boost the growth. Companies in the antihypertensive drugs market could also face challenges such as people not adhering to required medication due to lack of awareness or information. The details covered in the antihypertensive drugs market report cover all the aspects of the industry. antihypertensive drugs market analysts have also shared growth projections in the report and have suggested antihypertensive drugs market players to plan growth strategies accordingly.

Market Segmentation

The global antihypertensive drugs market has been segmented based on type, therapeutic class, and channel of distribution. On the basis of channel of distribution, the market for antihypertensive drugs is segmented based on e-commerce websites & online drug stores, hospital pharmacy, retail pharmacy, and others. Additionally, the market on the basis of type, is segmented into primary hypertension, secondary hypertension. The global market for antihypertensive drugs is also covered based on therapeutic class segment which is further split into ACE Inhibitors, ARBs, beta-adrenergic blockers, diuretics, renin inhibitors, vasodilators, calcium channel blockers, and others.

Factors like growing preference for combination therapy and rising interest from key companies in combination therapy support the antihypertensive drugs market growth. The performance of the antihypertensive drugs market has also been studied for the past and current years. Additionally, the antihypertensive drugs market report provides analysis of these segments. The antihypertensive drugs market segmental analysis provided in the report offers major details about the antihypertensive drugs market performance and future.

Request For Free Sample Copy : https://www.marketresearchfuture.com/sample_request/2347

Regional Overview

Companies in the antihypertensive drugs market are spread across the world. The antihypertensive drugs market report provides major information about regional markets of North America, Europe, Asia-Pacific (APAC), and the rest of the world. The North American antihypertensive drugs market has many companies across the United States, Canada, and Mexico. Europe has companies in the antihypertensive drugs market across Germany, France, Spain, Italy, and the United Kingdom. A detailed analysis of the antihypertensive drugs market across India, China, and Japan in the Asia-Pacific region is also presented in the report. The antihypertensive drugs market of the Middle East, Africa, and other regions has also been studied by analysts. The regional analysis of the antihypertensive drugs market can be found in the market research report.

Browse Complete Toc :https://www.marketresearchfuture.com/reports/anti-hypertensive-drugs-market-2347

Competitive Landscape

The antihypertensive drugs market is supported by high prevalence of sedentary lifestyle and expanding geriatric population around the world. The population growth around the world and increasing demand of antihypertensive drugs market based services and products also support the market growth. However, the antihypertensive drugs market growth can be affected due to low awareness in developing countries. The report covers all such details which will help companies in the antihypertensive drugs market to strengthen their business plan and improve their product portfolio. The antihypertensive drugs market research report also provides company profiles of major companies. The company profiles of many organizations operating in the antihypertensive drugs market report highlights crucial details like company size, revenue growth, and details of mergers and acquisitions taking place in the antihypertensive drugs market. New companies and established businesses can plan their strategies based on this data provided in the antihypertensive drugs market research report.

Industry News

United Therapeutics Corporation today announced a deal with the U.S. to obtain a Priority Approval Voucher for Rare Pediatric Disorder (PRV), which it plans to use for an upcoming New Drug Proposal (NDA) Administration of Food and Medicines (FDA). The PRV authorizes the holder to nominate an NDA for priority evaluation and, instead of the normal 12-month review cycle, allows for an expedited eight-month review. Following the closing of the deal, United Therapeutics plans to add the PRV, due in the first half of 2021, to its NDA for Tyvaso DPI.

Intraocular Lens Market : In-Depth Market Research Report 2019 – 2023

 

Market Highlights

It is estimated that the global intraocular lens market is expected to register a CAGR of ~ 5.43% during the forecast period of 2018–2023 with an estimated market value of USD 3.54 billion in 2017. Intraocular lens is implanted inside the eye substituting the eye’s natural lens. These lenses are very effective in nature and are used for the correction of numerous eye defects such as astigmatism, presbyopia, near-sightedness (myopia), and among others.

The rising prevalence of eye diseases, and high rate of adoption of premium intraocular lens technology is expected to drive the growth of the market extensively. Also, increase in the geriatric population and the rise in diabetic population is estimated to drive the growth of the intraocular lens market. According to the data published in 2015 by the Centers for Disease Control and Prevention (CDC), Refractive errors are the most frequent eye problems in the US. Also, according to the report published in 2016 by National Eye Institute, proper refractive eye correction could improve vision among 11 million Americans aged 12 years and older.

Factors such as post-operative complications, high cost of intraocular lens, and lack of skilled medical professionals are restraining the growth of market. Also, lack of reimbursement policies for premium lens in many developing and underdeveloped regions is anticipated to hinder the growth of the intraocular market.

The global intraocular lens market is currently dominated by many market players. The key players in the market are involved in strategic collaborations and new product launches to brace its market position. For instance, in December 2018, Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies Inc., received 510(k) clearance from the US Food and Drug Administration (FDA) for Bausch + Lomb ULTRA Multifocal for Astigmatic correction. Thus, the company broadened its product portfolio to hold its position in the market.

Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/7264

Regional Analysis

The market in the Americas is expected to dominate the global intraocular lens market during the forecast period owing to the rising healthcare expenditure. In addition, proactive government initiatives to spread awareness about the benefits of intraocular lens among the masses have supplemented the market growth. Europe is expected to hold the second largest position in the global intraocular lens market. The market growth in this region is attributed to the existence of a well-established healthcare system and increase in insurance coverage. Asia-Pacific is estimated to be the fastest growing region in the market due to the improving healthcare infrastructure. The market in the Middle East & Africa is likely to account for the smallest share of the global intraocular lens market.

Segmentation

The global intraocular lens market has been segmented into type, material and end user. The market, based on type, has been segmented into monofocal intraocular lens, multifocal intraocular lens, accommodating intraocular lens, phakic intraocular lens, and others.

The market, by material, has been segmented into hydrophobic acrylic, hydrophilic acrylic, polymethylmeth-acrylate (PMMA), and others.

The market, by end user has been segmented into hospitals, ophthalmic clinics, ambulatory surgical centers, and others.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/intraocular-lens-market-7264

Key Players

Some of the key players in the global intraocular lens market are Alcon, Inc., Bausch + Lomb, Eyekon Medical, Inc., Carl Zeiss Meditec, Johnson & Johnson Vision Care, Inc., HOYA Corporation, STAAR Surgical Company, Rayner Intraocular Lenses Limited, PhysIOL, Ophtec BV, Humanoptics AG, Lenstec, Inc., Oculentis GmbH, Aurolab, and Nidek Co., Ltd.

Surgical Sealants and Adhesives Market Overview, Dynamics, Growth Factors for Business Expansion, Key Companies, Trends and Forecast 2023

 

Market Highlights:

The Global Surgical Sealants and Adhesives Market is anticipated to have held a market value of USD 2.12 billion in the year 2017 and is expected to grow at a CAGR of 9.3% during the forecast period.

Growing prevalence and incidence of various disorders, growth in the number of accidents, and growth in the number of surgeries are expected to drive the growth of market. According to the Centers for Disease Control and Prevention (CDC), each year around 630,000 Americans die from heart disease. On other hand, lack of reimbursements policy; and extensive clinical data requirements for launching products can restrain the market growth over the assessment period.

Regional Analysis:

Geographically, the Americas is expected to dominate the global surgical sealants and adhesives market owing to the presence of well-developed healthcare sector, growing prevalence and incidence of various disorders, growth in the number of accidents, and growth in the number of surgeries. Europe is expected to hold the second largest position in the global surgical sealants and adhesives market owing to the growing prevalence of chronic diseases coupled with increasing adoption of new technologies. Asia-Pacific is expected to be the fastest growing market owing to the large population base of the diabetic patients and increasing developments in healthcare segment. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global surgical sealants and adhesives market.

Request For Free Sample Copy : https://www.marketresearchfuture.com/sample_request/7005

Segmentation:

The Global Surgical Sealants and Adhesives Market has been segmented into product, indication, and application.

Based on product, the surgical sealants and adhesives market is segmented into natural/biological sealants and adhesives; and synthetic and semisynthetic sealants and adhesives. The natural/biological sealants and adhesives segment is expected to account for the largest share and fastest growing segment of the global market in 2017. the natural/biological sealants and adhesives segment further sub segmented in to polypeptide/protein-based sealants and adhesives; and polysaccharide-based sealants and adhesives. Whereas, synthetic and semi-synthetic sealants and adhesives further segmented in to cyanoacrylates, polyethylene glycol hydrogels, urethane based, and others.

Based on indication, the surgical sealants and adhesives market is segmented into surgical hemostasis, tissue sealing, and tissue engineering.

Based on application, the surgical sealants and adhesives market is segmented into general surgeries, cardiovascular surgeries, central nervous system surgeries, orthopedic surgeries, urological surgeries, and others.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/surgical-sealants-and-adhesives-market-7005

Key Players:

Some of the prominent players in the global surgical sealants and adhesives market are C. R. Bard, Inc. (US), Johnson & Johnson (UK), Baxter International, Inc. (US), Medtronic plc (US), B. Braun Melsungen AG (Germany), Cohera Medical, Inc. (US), Sanofi Group (France), Sealantis, Ltd (Israel), Vivostat A/S (Denmark), and Ocular Therapuetix, Inc. (US)

Particle Therapy Market Overview: Type and Applications, Trends, Industry Analysis & Forecast, 2018-2023

 

Market Highlights:

Particle Therapy Market are used for the treatment of various type of cancer such as prostate cancer, lung cancer, pediatric cancer, head and neck cancer, breast cancer, and others by using most advanced areas of external beam radiation therapy.The increasing number of cancers affected population, increasing adoption of particle therapy, and rising particle therapy centers across the globe are the major factors driving the growth of the global particle therapy market. Additionally, increasing R&D spending and aggressive strategies adopted by the top players are fueling the growth of the market during forecast period. For instance, according to report published by Particle Therapy Co-Operative Group, in 2016, till 2014 around 1802 patients were treated with particle therapy. Whereas, in United States, around 78,613 cancer patients were treated with particle therapy till 2016.The high costs associated with establishments of centers and lack of reimbursement policy are likely to hinder market growth during the forecast period.

Regional Analysis:

The market is likely to dominate by Americas during the forecast period owing to the increasing prevalence of cancer patients, rising government focused towards establishment of particle therapy centers for treatment, and well-established healthcare sector in the region. The European market is expected to be the second-largest due to government funding and support of the healthcare sector, coupled with increasing research and development. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to technological development, increasing adoption of advance treatment from developed countries, and favorable government initiatives for healthcare facilities. The market in the Middle East & Africa is likely to account for the smallest share of the global particle therapy market.

Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/7000

Segmentation:

The Global Particle Therapy Market has been segmented on the basis of type, product & service, cancer type, system, and application.On the basis of type, the market has been segmented into proton therapy and heavy ion therapy. The particle therapy market, by product and services, has been segmented into products and services. Products are further classified into cyclotrons, synchrotrons, and synchrocyclotrons. On the basis of cancer type, the market has been divided into prostate cancer, lung cancer, pediatric cancer, head and neck cancer, breast cancer, and others. Based on system, market has been segmented into multi-room systems and single-room systems. On the basis of application, the market has been classified as treatment applications and research applications. The pediatric cancer segment is expected to hold the largest market share of the particle therapy market, by cancer type, during the forecast period. Also, research applications to register the highest CAGR in the global particle therapy market during the forecast period.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/particle-therapy-market-7000

Key Players:

Some of the key players in the global particle therapy market are Advanced Oncotherapy PLC., Danfysik A/S, Hitachi, Ltd., Ion Beam Applications Sa (IBA), Mevion Medical Systems, Inc., Optivus Proton Therapy, Inc., Protom International, Inc., Provision Healthcare, LLC, Sumitomo Heavy Industries, Ltd., Varian Medical Systems, Inc.

Immune Thrombocytopenia (ITP) Market Analysis, Market Status, Competition & Companies, Growth Opportunities, Top Key Players and Forecast by 2023

 

Market Highlights:

As per the latest report published by Market Research Future (MRFR), the Global Immune Thrombocytopenia (ITP) Market is set to surpass a valuation of USD 2,300 Mn by the year 2023, reflecting a healthy CAGR. ITP is a blood related disorder that cause abnormal clotting. Some of the discomforts caused by the disease include bruising, bleeding and severe drop in platelets counts. Both minors and adults can develop the condition. The disease is classified into primary and secondary form. Primary form of ITP occurs on its own while the latter is an offshoot of another condition. The condition can be triggered by reactive medications, autoimmune disease, pregnancy and certain type of cancers.

ITP is among the most commonly occurring disorder across the globe. In addition, the incidence rate has continued to spiral upwards in recent years. Factors as such as are fueling the demand for drugs and therapeutics for ITP. Currently, there are four treatment options available for ITP – intravenous   immune   globulin (IVIG), thrombopoietin receptor agonists, corticosteroids and immune-suppressing drugs. Though these treatment options have gained a healthy mileage, they come with certain degree of risk of side-effects. Nonetheless, increased focus towards innovation and R&D is likely to create new avenues for market players in the foreseeable future. 

Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/6996 

The report includes a thorough segmental analysis of the market on the basis of end-user, treatment, and type. By end-user, the market has been segmented into specialty centers, hospitals and clinics, research and academic institutes and others. Currently, the hospitals & clinic segment accounts for more than one-third share of the market. During the forecast period, the segment is expected to record an impressive 6.22% CAGR. By treatment, the market has been segmented into thrombopoietin receptor agonists, corticosteroids, intravenous immunoglobulins and others. In terms of value, the corticosteroids segment currently commands for close to 40% market share and is projected to surge at a CAGR of 5.57%. Based on type, the market has been segmented into acute immune thrombocytopenia and chronic immune thrombocytopenia. The chronic immune thrombocytopenia segment currently accounts for over two-third market and is expected to highly profitable in 2018 and beyond. The segment is likely to reach a valuation of USD 2,036.9 Mn by the end of assessment period, exhibiting a CAGR of 5.94%. Approval of numerous targeted treatments coupled with the rising prevalence of ITP is proving the impetus on the segment’s growth.

The market has been covered across regions such as Europe, Americas, the Middle East & Africa (MEA) and Asia Pacific (APAC). In 2017, the Americas segment accounted for the largest market share and trend is likely to continue beyond 2018. Some of the factors that are supporting the growth of the market in the region include rising prevalence of ITP in countries such as the US, Canada, Mexico and Brazil, high healthcare expenditure and favorable reimbursement policies. As per the National Organization of Rare Disorders (NORD), the incidence rate of Immune thrombocytopenia among Americans is 3.3 per 100,000 adults/year approx. Meanwhile, Europe and APAC currently hold the second and third spot respectively. Presence of advanced healthcare infrastructure and strong government support is supporting the growth of the market Europe. In Asia Pacific, the market has gained a healthy momentum in recent years owing to factors such as increase penetration of healthcare services, growing awareness and expanding patient pool. The market for ITP in APAC is expected to witness a strong growth over the next couple of years.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/immune-thrombocytopenia-itp-market-6996

Competition Tracking:

Key companies mentioned in MRFR’s report include Dova Pharmaceuticals, Jiangsu Hengrui Pharmaceutical Co., Ltd., Ligand Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., Kyowa Hakko Kirin Co., Ltd., Amgen Inc., Shire, F.Hoffmann-La Roche Ltd., Shionogi Inc. CSL Limited, and Novartis AG.

Immune Thrombocytopenia (ITP) Market Size: Development, Growth, Trends, Demand, Analysis and Forecast 2023

 

Market Highlights:

As per the latest report published by Market Research Future (MRFR), the Global Immune Thrombocytopenia (ITP) Market is set to surpass a valuation of USD 2,300 Mn by the year 2023, reflecting a healthy CAGR. ITP is a blood related disorder that cause abnormal clotting. Some of the discomforts caused by the disease include bruising, bleeding and severe drop in platelets counts. Both minors and adults can develop the condition. The disease is classified into primary and secondary form. Primary form of ITP occurs on its own while the latter is an offshoot of another condition. The condition can be triggered by reactive medications, autoimmune disease, pregnancy and certain type of cancers.

ITP is among the most commonly occurring disorder across the globe. In addition, the incidence rate has continued to spiral upwards in recent years. Factors as such as are fueling the demand for drugs and therapeutics for ITP. Currently, there are four treatment options available for ITP – intravenous  immune  globulin (IVIG), thrombopoietin receptor agonists, corticosteroids and immune-suppressing drugs. Though these treatment options have gained a healthy mileage, they come with certain degree of risk of side-effects. Nonetheless, increased focus towards innovation and R&D is likely to create new avenues for market players in the foreseeable future. 

Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/6996 

The report includes a thorough segmental analysis of the market on the basis of end-user, treatment, and type. By end-user, the market has been segmented into specialty centers, hospitals and clinics, research and academic institutes and others. Currently, the hospitals & clinic segment accounts for more than one-third share of the market. During the forecast period, the segment is expected to record an impressive 6.22% CAGR. By treatment, the market has been segmented into thrombopoietin receptor agonists, corticosteroids, intravenous immunoglobulins and others. In terms of value, the corticosteroids segment currently commands for close to 40% market share and is projected to surge at a CAGR of 5.57%. Based on type, the market has been segmented into acute immune thrombocytopenia and chronic immune thrombocytopenia. The chronic immune thrombocytopenia segment currently accounts for over two-third market and is expected to highly profitable in 2018 and beyond. The segment is likely to reach a valuation of USD 2,036.9 Mn by the end of assessment period, exhibiting a CAGR of 5.94%. Approval of numerous targeted treatments coupled with the rising prevalence of ITP is proving the impetus on the segment’s growth.

The market has been covered across regions such as Europe, Americas, the Middle East & Africa (MEA) and Asia Pacific (APAC). In 2017, the Americas segment accounted for the largest market share and trend is likely to continue beyond 2018. Some of the factors that are supporting the growth of the market in the region include rising prevalence of ITP in countries such as the US, Canada, Mexico and Brazil, high healthcare expenditure and favorable reimbursement policies. As per the National Organization of Rare Disorders (NORD), the incidence rate of Immune thrombocytopenia among Americans is 3.3 per 100,000 adults/year approx. Meanwhile, Europe and APAC currently hold the second and third spot respectively. Presence of advanced healthcare infrastructure and strong government support is supporting the growth of the market Europe. In Asia Pacific, the market has gained a healthy momentum in recent years owing to factors such as increase penetration of healthcare services, growing awareness and expanding patient pool. The market for ITP in APAC is expected to witness a strong growth over the next couple of years.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/immune-thrombocytopenia-itp-market-6996

Competition Tracking:

Key companies mentioned in MRFR’s report include Dova Pharmaceuticals, Jiangsu Hengrui Pharmaceutical Co., Ltd., Ligand Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., Kyowa Hakko Kirin Co., Ltd., Amgen Inc., Shire, F.Hoffmann-La Roche Ltd., Shionogi Inc. CSL Limited, and Novartis AG.

xyz Market Size: Development, Growth, Trends, Demand, Analysis and Forecast 2021

Corporate Wellness Market Set to Surge Significantly During 2017 to 2023

  Overview:

The global market report on Corporate Wellness Market is slated to grow substantially during the forecast period of 2018 to 2023. In 2017, the global market valuation was USD 49.7 billion. Market Research Future (MRFR) included several factors that can promote global market growth. During the forecast period from 2018 to 2023, the global market would rise with a 7% CAGR.

The global market would grow with the rising demand for plans to increase productivity, curbing of healthcare expenditure, growing number of white-collar workers, and others are expected to boost the global market investment. Such projects are expected to inspire morale and the quality of work of people associated with the company. It is also getting boosted by the changing consumption habit, smoking, obesity, and sedentary lifestyle. The rise in private sector Capex is expected to back the global corporate wellness market in the coming days.

Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/6963 

Segmentation:

The global report on the corporate wellness market has been studied on the basis of a segmentation that includes the category, service type, and end user. These segments have data supported by facts, figures, graphs, and charts that can help in understanding the market flow and boost procedures of developing strategies.

By service type, the study on the corporate wellness market includes stress management, health risk assessment, health screening, smoking cessation, fitness, nutrition & weight management, and others. In 2017, the health risk assessment segment had the largest market valuation, which has been inspired by the rising adoption of wellness programs that aims to identify health risks and prevent any kind of health risks.

By category, the report on the global understanding of the corporate wellness market has been segmented into psychological therapists, fitness & nutrition consultants, and organizations. The fitness & nutrition consultants segment is expected to make substantial progress in the coming days.

By end user, the study on the corporate wellness market includes medium-scale businesses, small-scale businesses, and large-scale businesses. The large-scale businesses can inspire the market in the coming days.

Regional Analysis:

The global market for corporate wellness has been studied on the basis of regional analysis as well. The Americas is leading the market ahead as their structured system is helping them to plan various actions. Major multinational companies are contributing much to the growth of the market. In Europe, this growth will be substantial as major companies have structured their mainframe with corporate wellness integrated into the model.

Competitive Landscape:

Wellness Corporate Solutions, LLC, ComPsych Corporation, Central Corporate Wellness, SOL Wellness, Wellsource, Inc., Virgin Pulse, Marino Wellness, Truworth Health Technologies Pvt. Ltd., The Vitality Group, Inc., EXOS, Privia Health, Sodexo Group, Bupa Wellness Pty Ltd, ProvantHealth (Hooper Holmes, Inc.), and 1to1help.net Pvt. Ltd. are some of the major companies playing big in the global corporate wellness market. These companies have launched various strategic moves to inspire better growth for themselves and influence holistic growth for the market. MRFR recorded all the recent moves implemented by these companies to understand trends that are governing the market or may impact it in the coming days.

Browse Complete Toc :https://www.marketresearchfuture.com/reports/corporate-wellness-market-6963 

Industry News:

The COVID-29 crisis has led to a drastic change in the corporate wellness culture. Various corporate companies have started exploring opportunities in the market as they want to build their credibility among their employees. Also, they are much stressed about their employees who are fighting in the front lines. These companies have announced packages saying they would cover the bills of their employees if they contract the disease. This has also influenced tie-ups.